Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Figures/Tables List
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Published comments/rapid response letters
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Ärnlöv, J.
space
  arrow  Vasan, R. S.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

ARTICLE

Endogenous Sex Hormones and Cardiovascular Disease Incidence in Men

right arrow Johan Ärnlöv, MD, PhD; Michael J. Pencina, PhD; Shreyasee Amin, MD; Byung-Ho Nam, PhD; Emelia J. Benjamin, MD, ScM; Joanne M. Murabito, MD, ScM; Thomas J. Wang, MD; Philip E. Knapp, MD; Ralph B. D'Agostino, Sr., PhD; Shalendar Bhasin, MD; and Ramachandran S. Vasan, MD

1 August 2006 | Volume 145 Issue 3 | Pages 176-184

Background: Data suggest that endogenous sex hormones (testosterone, dehydroepiandrosterone sulfate [DHEA-S], and estradiol) influence cardiovascular disease (CVD) risk factors and vascular function. Yet, prospective studies relating sex hormones to CVD incidence in men have yielded inconsistent results.

Objective: To examine the association of circulating sex hormone levels and CVD risk in men.

Design: Prospective cohort study.

Setting: Community-based study in Framingham, Massachusetts.

Participants: 2084 middle-aged white men without CVD at baseline.

Measurements: The authors used multivariable Cox regression to relate baseline levels of testosterone, DHEA-S, and estradiol to the incidence of CVD (coronary, cerebrovascular, or peripheral vascular disease or heart failure) during 10 years of follow-up.

Results: During follow-up, 386 men (18.5%) experienced a first CVD event. After adjustment for baseline standard CVD risk factors, higher estradiol level was associated with lower risk for CVD (hazard ratio per SD increment in log estradiol, 0.90 [95% CI, 0.82 to 0.99]; P = 0.035). The authors observed effect modification by age: Higher estradiol levels were associated with lower CVD risk in older (median age >56 years) men (hazard ratio per SD increment, 0.86 [CI, 0.78 to 0.96]; P = 0.005) but not in younger (median age ≤56 years) men (hazard ratio per SD increment, 1.11 [CI, 0.89 to 1.38]; P = 0.36). The association of higher estradiol level with lower CVD incidence remained robust in time-dependent Cox models (updating standard CVD risk factors during follow-up). Serum testosterone and DHEA-S levels were not statistically significantly associated with incident CVD.

Limitations: Sex hormone levels were measured only at baseline, and the findings may not be generalizable to women and nonwhite people.

Conclusions: In the community-based sample, a higher serum estradiol level was associated with lower risk for CVD events in older men. The findings are consistent with the hypothesis that endogenous estrogen has vasculoprotective influences in men.


Editors' Notes
space

Context

  • Studies of the role of endogenous sex hormones in cardiovascular disease (CVD) in men have been inconclusive.

Contribution

  • A total of 2084 men from 2 Framingham Heart Study cohorts had levels of total serum estrogen, testosterone, and dehydroepiandrosterone sulfate (DHEA-S) measured in 1981 to 1985 for the original cohort and in 1987 to 1991 for the offspring cohort. Testosterone and DHEA-S levels were not associated with CVD risk. Estrogen levels were inversely related: Risk for CVD in the highest quartile was 0.68 (95% CI, 0.50 to 0.92) times that in the lowest level.

Cautions

  • Investigators studied only white men and did not study free unbound hormone levels.

Implications

  • Endogenous estrogen may be vasculoprotective in men, which is in contrast to the effects of exogenous estrogen.

—The Editors

 

Author and Article Information
space

From the National Heart, Lung, and Blood Institute's Framingham Heart Study, National Institutes of Health, Bethesda, Maryland; Boston University School of Medicine, Boston University, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts; Mayo Clinic College of Medicine, Rochester, Minnesota; and Uppsala University, Uppsala, Sweden.

Acknowledgments: The authors acknowledge the assistance of Ms. Pamela Bacharach, who performed all the sex hormone assays, and Clark Sawin, MD, who supervised the assays. Dr. Sawin passed away in August 2004.

Grant Support: By a Bergmarks travel grant, a Viking Björks Hedersledamotstipendium, a Capio travel grant, and the Thuréus Foundation and through research grants (National Heart, Lung, and Blood Institute contracts N01-HC-25195, 6R01-NS 17950, K23 HL074077, and 2K24 HL04334) from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Potential Financial Conflicts of Interest: Consultancies: T.J. Wang (Novartis Institutes for Biomedical Research); Grants received: S. Bhasin (Solvay Pharmaceuticals).

Requests for Single Reprints: Ramachandran S. Vasan, MD, Boston University School of Medicine, Framingham Heart Study, 73 Mount Wayte Avenue, Suite 2, Framingham, MA 01702-5803; e-mail, vasan{at}bu.edu.

Current Author Addresses: Dr. Ärnlöv: Section of Geriatrics, Uppsala University, PO Box 609, 75215 Uppsala, Sweden.

Drs. Pencina and D'Agostino Sr.: Mathematics Department, Boston University, 111 Cummington Street, Boston, MA 02215.

Dr. Amin: Division of Rheumatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55902.

Drs. Nam, Benjamin, Murabito, Wang, and Vasan: Boston University School of Medicine, Framingham Heart Study, 73 Mount Wayte Avenue, Suite 2, Framingham, MA 01702-5803.

Drs. Knapp and Bhasin: Endocrinology Division, Department of Medicine, Boston University School of Medicine, 670 Albany Street, 2nd Floor, Boston, MA 02118.

Author Contributions: Conception and design: J. Ärnlöv, B.-H. Nam, J.M. Murabito, R.S. Vasan.

Analysis and interpretation of the data: J. Ärnlöv, M.J. Pencina, S. Amin, B.-H. Nam, J.M. Murabito, R.B. D'Agostino Sr., S. Bhasin, R.S. Vasan.

Drafting of the article: J. Ärnlöv, M.J. Pencina, B.-H. Nam, S. Bhasin, R.S. Vasan.

Critical revision of the article for important intellectual content: J. Ärnlöv, M.J. Pencina, S. Amin, B.-H. Nam, E.J. Benjamin, T.J. Wang, P.E. Knapp, R.B. D'Agostino Sr., S. Bhasin, R.S. Vasan.

Final approval of the article: J. Ärnlöv, M.J. Pencina, S. Amin, B.-H. Nam, E.J. Benjamin, J.M. Murabito, T.J. Wang, R.B. D'Agostino Sr., S. Bhasin, R.S. Vasan.

Statistical expertise: M.J. Pencina, B.-H. Nam, R.B. D'Agostino Sr.

Obtaining of funding: R.S. Vasan.

Administrative, technical, or logistic support: R.B. D'Agostino Sr., R.S. Vasan.

Collection and assembly of data: S. Amin, R.S. Vasan.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
I. Peter, A. Kelley-Hedgepeth, C. S. Fox, L. Adrienne Cupples, G. S. Huggins, D. E. Housman, R. H. Karas, M. E. Mendelsohn, D. Levy, and J. M. Murabito
Variation in Estrogen-Related Genes Associated with Cardiovascular Phenotypes and Circulating Estradiol, Testosterone, and Dehydroepiandrosterone Sulfate Levels
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2779 - 2785.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K.-T. Khaw, M. Dowsett, E. Folkerd, S. Bingham, N. Wareham, R. Luben, A. Welch, and N. Day
Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study
Circulation, December 4, 2007; 116(23): 2694 - 2701.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Tivesten, D. Mellstrom, H. Jutberger, B. Fagerberg, B. Lernfelt, E. Orwoll, M. K. Karlsson, O. Ljunggren, and C. Ohlsson
Low Serum Testosterone and High Serum Estradiol Associate With Lower Extremity Peripheral Arterial Disease in Elderly Men: The MrOS Study in Sweden
J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1070 - 1076.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
M. J. Walton, N. Kumar, D. T. Baird, H. Ludlow, and R. A. Anderson
7{alpha}-Methyl-19-Nortestosterone (MENT) vs Testosterone in Combination With Etonogestrel Implants for Spermatogenic Suppression in Healthy Men
J Androl, September 1, 2007; 28(5): 679 - 688.
[Abstract] [Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
Sex Hormones and CVD in Men
Journal Watch Cardiology, September 27, 2006; 2006(927): 7 - 7.
[Full Text]


Home page
JWatch GeneralHome page
Estradiol and Cardiovascular Disease in Men
Journal Watch (General), September 19, 2006; 2006(919): 4 - 4.
[Full Text]


Home page
BMJHome page
K. Fister
What's new in the other general journals
BMJ, August 12, 2006; 333(7563): 344 - 345.
[Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

REGULATION OF BIGLYCAN EXPRESSION BY SEX HORMONES UNIFIES THE CLINICAL TENETS OF ATHEROSCLEROSIS
Melvin K. Leow
Annals Online, 4 Aug 2006 [Full text]



 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2006 by the American College of Physicians.